TumorSight Viz

by SimBioSys  · Based in United States → — Redefine precision medicine. Revolutionize patient care. Defeat cancer.
General Surgery Oncology Radiology

Subscription-based
Regulatory Status Disclosed

Overview

TumorSight Vizby SimBioSys is an AI-powered, cloud-based 3D visualization and image processing platform designed to assist in preoperative planning for early-stage breast cancer patients.

The platform is primarily built for breast surgeons, surgical oncologists, and multidisciplinary clinical teamsoperating in hospital and outpatient surgical settings. It serves as a clinical decision support tool prior to surgical interventions, such as breast-conserving surgery or mastectomies.

Workflow Integration & Capabilities:

  • Automated Image Transfer:Integrates directly with hospital Picture Archiving and Communication Systems (PACS) to automate DICOM image transfers, minimizing manual administrative tasks.
  • AI-Driven Segmentation:Automatically segments the tumor alongside surrounding anatomical structures, including fibroglandular tissue, adipose tissue, skin, blood vessels, and the chest wall.
  • Quantitative Clinical Metrics:Calculates key physical measurements, such as total tumor volume, tumor-to-breast volume ratios, and exact distances from the tumor to critical landmarks like the skin, chest wall, and nipple.
  • Surgical Margin Planning:Features a convex hull tool that allows surgeons to visualize hypothetical resection margins to guide surgical approaches.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • 3D spatial visualizations of breast cancer
  • Converts standard breast MRI into intuitive 3D models
  • Automatic segmentation and quantification of tumor characteristics
  • Calculates tumor volume and distances to anatomical features
  • Supports breast conservation surgery planning
  • Enables shared decision-making between surgeon and patient
  • Research-use application to convert prone imaging to supine operative position
  • AI-driven segmentation for enhanced preoperative planning
  • Provides same-day results and insights
  • PACS connectivity for automated image transfer

Use Cases

  • Preoperative planning for breast cancer surgery
  • Enhancing surgical decision-making (margins, incisions, reconstruction)
  • Patient education and shared decision-making
  • Determining breast conservation versus mastectomy options
  • Improving consistency, precision, and efficiency in breast cancer surgery
  • Research applications in tumor modeling and visualization

What Physicians Need to Know

Key Capabilities
TumorSight Viz converts standard breast MRI into interactive, patient-specific 3D visualizations, providing surgeons with detailed anatomical insight for surgical planning. It automatically segments and displays tumor shape, size, morphology, and location, along with surrounding anatomical structures like skin, vessels, chest, fat, and gland. The tool provides accurate volume measurements for tumors and breasts, and calculates tumor-to-landmark measurements to aid in planning breast-conserving surgery. A research-use application can convert prone MRI images to a supine operative position for enhanced surgical and reconstructive visualization.
Clinical Utility
TumorSight Viz is intended for visualization and analysis of breast MRI studies in patients with biopsy-proven early-stage or locally advanced breast cancer. It supports more informed and individualized surgical decision-making, helping surgeons assess breast-conserving options and plan oncoplastic techniques. The 3D models and measurements enhance collaborative decision-making between surgeons and patients, potentially minimizing surgery severity and improving quality of life. It can help determine whether to preserve a breast or choose a mastectomy before a procedure begins.
Integration Options
TumorSight Viz is a cloud-based platform accessible on an off-the-shelf computer. It integrates with hospital PACS systems to automate image transfer and streamline workflows. The technology is designed to fit naturally into existing workflows, taking routine breast MRIs as input without disrupting radiology or surgical processes.
Compliance Status
TumorSight Viz is FDA-cleared. It has received multiple FDA 510(k) clearances, with its third clearance expanding its functionality and integration capabilities.
Pricing Model
Unknown
User Experience
The platform provides intuitive, interactive 3D visualizations. Surgeons can easily manipulate the 3D visualization on a computer screen. Most surgeons are comfortable reviewing cases after a short onboarding session, supported by guided training and ongoing clinical support. Surgeons have reported that TumorSight Viz changes how they plan cases, valuing the ability to see tumor geometry, margins, and relationships to critical structures in 3D, and that it reduces uncertainty.
Support Quality
SimBioSys provides ongoing clinical support to users.
Implementation Complexity
The tool is designed to be easy to use and integrate into existing workflows. It is a cloud-based platform, requiring an off-the-shelf computer for access.
Evidence Base
Clinical studies demonstrate strong concordance with radiologist annotations, accurate delineation of tumor size relative to breast volume, and consistent performance across more than 1,600 retrospective cases from over nine institutions. The deep-learning model used by TumorSight Viz was developed on a large dataset of de-identified breast cancer patient DCE-MRIs. Performance validation studies have shown high degrees of overlap between TumorSight Viz and ground-truth convex hulls. The multi-institutional nature of the segmentation model's training and testing sets provides a basis for broad generalizability.
Physician Tip

Leverage TumorSight Viz for comprehensive 3D visualization of breast tumors and surrounding anatomy to enhance surgical planning and patient communication. Utilize the accurate volume and landmark measurements to optimize breast-conserving surgery and assess mastectomy options. The tool's ability to convert prone MRI to supine (research use) can further aid in surgical and reconstructive visualization. Integrate the 3D models into patient discussions to improve understanding and shared decision-making.

TumorSight Viz is a cloud-based platform that integrates with hospital PACS systems for automated image transfer, streamlining workflows without disrupting existing radiology or surgical processes. This allows for seamless incorporation into current clinical environments.

Details

Category Oncology AI
Pricing Subscription-based
DeploymentCloud-based
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status Cleared AI-estimated
Integrations
EHR Not specified
Specialties General Surgery, Oncology, Radiology

FDA clearance history

This product’s FDA authorization. From FDA’s list of AI-enabled medical devices; each number links to FDA’s record.

Decision dateNumberName as listed by FDA
2025-07-08K251766 510(k)TumorSight Viz

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate TumorSight Viz

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money
No press coverage or publications on file yet. Know of some? Suggest an edit →

Videos

Product demos, reviews, and walkthroughs for TumorSight Viz.

No videos found. Search YouTube directly

View all on YouTube

Frequently Asked Questions

TumorSight Viz is designed to complement existing diagnostic workflows. It processes standard-of-care DCE-MRI images and pathology data, integrating with PACS systems for seamless image transfer. The platform provides 3D spatial visualizations and key metrics to aid in treatment planning, particularly for breast-conserving surgery, without requiring additional tissue samples or specialized hardware.
TumorSight Viz is an FDA-cleared medical device, having received multiple 510(k) clearances. It is intended for use in the visualization and analysis of breast MRI studies for patients with biopsy-proven early-stage or locally advanced breast cancer. The software is HIPAA compliant.
While TumorSight Viz provides valuable 3D visualizations and measurements, patient management decisions should not be made solely based on its results. The training data for the segmentation model had limitations, such as being primarily from subjects eligible for neoadjuvant chemotherapy, and may have had heterogeneous or extreme fibroglandular tissue, moderate or marked background parenchymal enhancement, and non-mass enhancement.
While other 3D breast tumor segmentation models exist, TumorSight Viz offers specific benefits such as segmenting and visually mapping five additional tissue types, providing a comprehensive 'lay of the land' with key anatomical landmarks. It expands upon existing DCE-MRI visualization platforms like DynaCAD and CADstream.
TumorSight Viz analyzes existing DCE-MRI images and pathology data at a fraction of the cost of gene expression tests, making advanced analysis more accessible. The pricing model for TumorSight Viz is enterprise-based.
TumorSight Viz provides critical measurements like tumor volume, tumor-to-breast volume, and distances to anatomical structures, which help surgeons determine whether to pursue breast-conserving surgery or a mastectomy. It also offers a clinical decision support (CDS) feature that informs providers of evidence-based treatment options, aligning with guidelines for minimally invasive approaches.
Yes, TumorSight Viz creates clear 3D 'digital twin' renderings of the tumor within auto-segmented anatomical structures. This 360° depiction of the tumor and surrounding tissues is designed to enhance collaborative decision-making between the surgeon and patient, helping patients visualize their care and fostering trust and understanding.

Related Tools

VERITON CT 400 Series Digital SPECT/CT System (VERITON CT 416/464)
Spectrum Dynamics Medical
Oncology AI
The VERITON CT 400 Series is a digital SPECT/CT system with a 360-degree gantry and 12 swiveling CZT detectors, offering high sensitivity and quantitative accuracy for a wide range of nuclear medicine applications, including advanced theranostics imaging.
syngo.via MI Workflows, syngo MBF
Siemens Medical Solutions USA
Cardiology AI
syngo.via MI Workflows, syngo MBF is an intelligent, integrated imaging software that helps address the challenges of interpreting, managing, and sharing complex data from molecular imaging scanners, providing automated workflows and advanced visualization for various clinical applications.
syngo.via MI WorkFlows, Scenium, syngo MBF
Siemens Medical Solutions USA
Cardiology AI
syngo.via MI Workflows, Scenium, and syngo MBF are medical diagnostic post-processing applications for viewing, manipulation, quantification, analysis, and comparison of PET or nuclear-medicine functional data with CT or MR anatomical data across timepoints, supporting disease management and radiotherapy treatment planning by trained healthcare professionals.
BIOGRAPH One
Siemens Healthineers AG
Oncology AI
BIOGRAPH One is a second-generation PET/MR scanner designed to transform PET/MR image quality for a new era, combining high PET precision with powerful MR performance. It enables simultaneous visualization of organ location, function, and cellular metabolism, offering faster image acquisition times and more efficient workflows than previous generations of PET/MR scanners.
Claire™ OCT System
Perimeter Medical Imaging AI
Oncology AI
Perimeter Medical Imaging AI is a medical technology company driven to transform cancer surgery with ultra-high resolution, real-time, advanced imaging tools that address unmet medical needs.S. for intraoperative breast cancer margin assessment.
syngo.via RT Image Suite VC10
Varian Medical Systems, Inc.
Clinical Decision Support & Reference
syngo.via RT Image Suite VC10 offers advanced imaging and workflow solutions for precise and efficient radiation therapy planning.

See all Oncology AI tools →

Suggest an Edit → | Report an issue | Last Verified: 2026-11-14 | First Added: 2026-04-19

Investors who backed TumorSight Viz

Funded through the company that built this tool.

AI Tool Finder
AI-powered search. Results may not be comprehensive.